Literature DB >> 12270057

Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma.

Riikka Räty1, Kaarle Franssila, Heikki Joensuu, Lasse Teerenhovi, Erkki Elonen.   

Abstract

OBJECTIVES: Mantle cell lymphoma (MCL) is characterised by translocation t(11;14) (q13;q32) leading to rearrangement of bcl1/CCND1 and overexpression of the cell-cycle regulatory protein cyclin D1. We assessed the significance of the cell proliferation rate as an outcome predictor with the five components of the International Prognostic Index (IPI) and the histological subtypes of MCL. PATIENTS AND METHODS: The hospital case records and histopathological material of 127 patients diagnosed with MCL in a single centre were reviewed. The cell proliferation rate was assessed by Ki-67 immunostaining and mitosis counting. Cox's multivariate regression model was used in multivariate survival analyses. The median follow-up time was 87 months.
RESULTS: The mantle zone/nodular subtype of the common variant (19%) was associated with median survival of 70 months, the diffuse subtype of the common variant (64%) of 35 months, and the blastoid subtype (17%) of 11 months (P < 0.001). Patients with Ki-67 expression in > or = 26% (the upper tertile) of the lymphoma cells had median survival of only 13 months as compared with 45 months in the rest of the patients (P < 0.001). In a multivariate analysis high Ki-67 expression, Ann Arbor stage III-IV, and age over 60 yr had independent influence on survival, whereas serum lactate dehydrogenase level, the number of extranodal disease sites, and performance status did not.
CONCLUSIONS: The IPI may not be an optimal tool for outcome prediction in MCL, and a better prognostic index may be obtained by including Ki-67 expression and possibly the histological subtype in the index.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270057     DOI: 10.1034/j.1600-0609.2002.01677.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  20 in total

1.  A novel quantitative PCR of proliferation markers (Ki-67, topoisomerase IIalpha, and TPX2): an immunohistochemical correlation, testing, and optimizing for mantle cell lymphoma.

Authors:  Helena Brizova; Marketa Kalinova; Lenka Krskova; Marcela Mrhalova; Roman Kodet
Journal:  Virchows Arch       Date:  2010-04-24       Impact factor: 4.064

2.  Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice.

Authors:  Ek Sara; Carl Ak Borrebaeck
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

3.  The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.

Authors:  E Sánchez-Tilló; L Fanlo; L Siles; S Montes-Moreno; A Moros; G Chiva-Blanch; R Estruch; A Martinez; D Colomer; B Győrffy; G Roué; A Postigo
Journal:  Cell Death Differ       Date:  2013-09-06       Impact factor: 15.828

4.  Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases.

Authors:  Pavla Veselá; Zbyněk Tonar; David Sálek; Samuel Vokurka; Marek Trněný; Roman Kodet; Mojmír Moulis; Petra Kašparová; Zdeňka Vernerová; Zuzana Velenská; Jan Stříteský; Michal Michal; Ludmila Boudová
Journal:  Virchows Arch       Date:  2014-07-22       Impact factor: 4.064

Review 5.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

6.  Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.

Authors:  Christian H Geisler; Arne Kolstad; Anna Laurell; Niels S Andersen; Lone B Pedersen; Mats Jerkeman; Mikael Eriksson; Marie Nordström; Eva Kimby; Anne Marie Boesen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Måns Akerman; Mats Ehinger; Christer Sundström; Ruth Langholm; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen
Journal:  Blood       Date:  2008-07-14       Impact factor: 22.113

7.  CD30 expression and proliferative fraction in nontransformed mycosis fungoides.

Authors:  James T Edinger; Beth Z Clark; Brian E Pucevich; Larisa J Geskin; Steven H Swerdlow
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

8.  The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.

Authors:  Harald Holte; Klaus Beiske; Merrill Boyle; Gunhild Trøen; Yngvild N Blaker; June Myklebust; Sunniva Kvaløy; Andreas Rosenwald; Ole C Lingjaerde; Lisa M Rimsza; Erlend B Smeland; David W Scott; Arne Kolstad
Journal:  Br J Haematol       Date:  2018-08-06       Impact factor: 6.998

Review 9.  Current management of mantle cell lymphoma.

Authors:  Oliver Weigert; Michael Unterhalt; Wolfgang Hiddemann; Martin Dreyling
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma.

Authors:  R Schaffel; C V Hedvat; J Teruya-Feldstein; D Persky; J Maragulia; D Lin; C S Portlock; C H Moskowitz; A D Zelenetz
Journal:  Ann Oncol       Date:  2010-01       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.